Pfizer seeks breakthrough with new product lineup amid patent expiration risks
PFE Pfizer Inc
$28.00 +1.82%
View chart & analysis → - 1Pfizer exceeded revenue estimates in 9 out of the last 10 reported quarters and exceeded earnings per share estimates in 10 quarters.
- 2Eliquis and Ebrenzo accounted for approximately 23% of Pfizer's $15 billion revenue in the second quarter.
- 3Pfizer is currently conducting 31 Phase 3 clinical studies.
So what's the key point?
Pfizer has consistently earned more revenue and profit than experts expected. The company is looking for a breakthrough by conducting research to create 31 new drugs.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.